Blog
Notes from the Peply team
Compound deep-dives, regulatory updates, guides, and announcements.
Regulatory
FDA Moves 12 Peptides Out of Category 2: What Secretary Kennedy's Announcement Means
HHS Secretary Kennedy announced April 15, 2026 that the FDA will begin removing 12 peptides from Category 2. Here is what happened, which compounds are affected, and what comes next.
3 min read
#FDA#Category 2#reclassification#BPC-157
Announcement
Introducing Peply: A Neutral Peptide Reference Tool
Peply is a vendor-independent reconstitution calculator and reference layer for peptide and injectable medication data. 27 compounds, 5 stacks, regulatory tracking, zero vendor affiliations.
4 min read
#launch#peptides#calculator#reference
Compound Update
Retatrutide in 2026: Current Research and Where It Stands
Retatrutide is Eli Lilly's Phase 3 investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Here is what the TRIUMPH data shows, how it compares to semaglutide and tirzepatide, and what regulatory status means in 2026.
7 min read
#retatrutide#GLP-1#weight-loss#Eli Lilly